POM-V
Prescription Required
Companion Animal
Moxiclear 40 mg + 10 mg Spot-on Solution for Small Dogs
Active ingredients: Imidacloprid, Moxidectin
Form
Spot-on
Species
Dogs
Manufacturer
Norbrook Laboratories Limited
VMD MA No.
02000/4437
What it's used for
The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Imidacloprid + Moxidectin
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Moxiclear 40 mg + 10 mg Spot-on Solution for Small Dogs — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
The veterinary medicinal product can be used as part of a treatment strategy for
flea allergy dermatitis (FAD).
flea allergy dermatitis (FAD).
AN: 01494/2024 & 02361/2024
Dosage schedule for dogs:
The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5
mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight the veterinary
medicinal product for dogs.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
The treatment schedule should be based on individual veterinary diagnosis and on the
local epidemiological situation.
Weight of dogPipette size to be usedVolume
Imidacloprid
[mg/kg bw]
Moxidectin
[mg/kg bw]
≤ 4 kg
Veterinary medicinal product
for small dogs
0.4 mlminimum of 10
minimum of
2.5
> 4 ≤ 10 kg
Veterinary medicinal product
for medium dogs
1.0 ml10–252.5–6.25> 10 ≤ 25 kg
Veterinary medicinal product
for large dogs
2.5 ml10–252.5–6.25> 25 ≤ 40 kg
Veterinary medicinal product
for very-large dogs
4.0 ml10–162.5–4
> 40 kgthe appropriate combination of pipettes
Flea treatment and prevention Ctenocephalides felis)
One treatment prevents future flea infestation for 4 weeks. Existing pupae in the
environment may emerge for 6 weeks or longer after treatment is initiated, depending
upon climatic conditions. Therefore, it may be necessary to combine the veterinary
medicinal product treatment with environmental treatments aimed at breaking the flea
life cycle in the surroundings. This can result in a more rapid reduction in the household
flea population. The veterinary medicinal product should be administered at monthly
intervals when used as part of a treatment strategy for flea allergy dermatitis.
Treatment of biting lice (Trichodectes canis)
A single dose of the veterinary medicinal product should be administered. A further
veterinary examination 30 days after treatment is recommended as some animals may
require a second treatment.
Treatment of ear mite infestation (Otodectes cynotis)
A single dose of the veterinary medicinal product should be administered. Loose debris
should be gently removed from the external ear canal at each treatment. A further
veterinary
examination 30 days after treatment is recommended as some animals may require a
second treatment. Do not apply directly to the ear canal.
AN: 01494/2024 & 02361/2024
Treatment of sarcoptic mange (caused by Sarcoptes scabiei
A single dose of the veterinary medicinal product should be administered twice 4 weeks
apart.
Prevention of heartworm disease (D. immitis) and cutaneous dirofilariosis (D. repens)
Dogs in areas endemic for heartworm, or those which have travelled to endemic areas,
may be infected with adult heartworms. Therefore prior to treatment with the veterinary
medicinal product, the advice provided in section 3.5 should be considered.
For prevention of heartworm disease and cutaneous dirofilariosis, the veterinary
medicinal product must be applied at regular monthly intervals during the time of the
year when mosquitoes (the intermediate hosts which carry and transmit
and D. repens
administered throughout the year or at least 1 month before the first expected
exposure to mosquitoes. Treatment should continue at regular monthly intervals until
1 month after the last exposure to mosquitoes. To establish a treatment routine, it is
recommended that the same day or date be used each month. When replacing
another heartworm preventative product in a heartworm prevention programme, the
first treatment with the veterinary medicinal product must be given within 1 month of
the last dose of the former medication.
In non-endemic areas there should be no risk of dogs having heartworm. Therefore,
they can be treated without special precautions.
Treatment of microfilariae (D. immitis)
The veterinary medicinal product should be administered monthly for two consecutive
months.
Treatment of cutaneous dirofilariosis (skin worm) (adult stages of Dirofilaria repens)
The veterinary medicinal product should be administered monthly for six consecutive
months.
Reduction of microfilariae (D. repens)
The veterinary medicinal product should be administered monthly for four consecutive
months. Efficacy against adult worms has not been shown. Adult worms may
continue to produce microfilariae.
Treatment and prevention of Angiostrongylus vasorum
A single dose of the veterinary medicinal product should be administered. A further
veterinary examination 30 days after treatment is recommended as some animals
may require a second treatment.
In endemic areas regular 4 weekly application will prevent angiostrongylosis and
patent infection with Angiostrongylus vasorum
AN: 01494/2024 & 02361/2024
Treatment of Crenosoma vulpis
A single dose of the veterinary medicinal product should be administered.
Prevention of Spirocerca lupi:
The veterinary medicinal product should be administered monthly.
Roundworm, hookworm and whipworm treatment (Toxocara canis, Ancylostoma
caninum, Uncinaria stenocephalaoxascaris leonina and Trichuris vulpis).
In areas endemic for heartworm, monthly treatment may significantly reduce the risk
of re-infection caused by the respective round-, hook- and whipworms. In areas non-
endemic for heartworm, the veterinary medicinal product can be used as part of a
seasonal prevention programme against fleas and gastrointestinal nematodes.
Studies have shown that monthly treatment of dogs will prevent infections caused by
Uncinaria stenocephala.
Method of administration
For external use only. Do not remove the pipette from the sachet until ready to use.
Remove the pipette from the outer sachet using scissors or fold along diagonal line to
expose nick; tear back at nick.
Hold the pipette upright. Tap the narrow part of the pipette to ensure the contents
remain within the main body of the pipette. Twist or snap back the tip.
For dogs up to 25 kg:
With the dog in a standing position, part the coat between the shoulder blades until
the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the
pipette on the skin and squeeze the pipette firmly several times to empty its contents
directly onto the skin.
AN: 01494/2024 & 02361/2024
For dogs of more than 25 kg:
For easy application the dog should be standing. The entire contents of the pipette
should be applied evenly as 3 or 4 spots along the top of the back, from between the
shoulders to the base of the tail. At each spot, part the coat until the skin is visible.
Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin
and gently squeeze the pipette to expel a portion of its contents directly onto the skin.
Do not apply an excessive amount of solution at any one spot, as that could cause
some of the veterinary medicinal product to run down the animal’s side.
Dosage schedule for dogs:
The recommended minimum doses are 10 mg/kg bodyweight imidacloprid and 2.5
mg/kg bodyweight moxidectin, equivalent to 0.1 ml/kg bodyweight the veterinary
medicinal product for dogs.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
The treatment schedule should be based on individual veterinary diagnosis and on the
local epidemiological situation.
Weight of dogPipette size to be usedVolume
Imidacloprid
[mg/kg bw]
Moxidectin
[mg/kg bw]
≤ 4 kg
Veterinary medicinal product
for small dogs
0.4 mlminimum of 10
minimum of
2.5
> 4 ≤ 10 kg
Veterinary medicinal product
for medium dogs
1.0 ml10–252.5–6.25> 10 ≤ 25 kg
Veterinary medicinal product
for large dogs
2.5 ml10–252.5–6.25> 25 ≤ 40 kg
Veterinary medicinal product
for very-large dogs
4.0 ml10–162.5–4
> 40 kgthe appropriate combination of pipettes
Flea treatment and prevention Ctenocephalides felis)
One treatment prevents future flea infestation for 4 weeks. Existing pupae in the
environment may emerge for 6 weeks or longer after treatment is initiated, depending
upon climatic conditions. Therefore, it may be necessary to combine the veterinary
medicinal product treatment with environmental treatments aimed at breaking the flea
life cycle in the surroundings. This can result in a more rapid reduction in the household
flea population. The veterinary medicinal product should be administered at monthly
intervals when used as part of a treatment strategy for flea allergy dermatitis.
Treatment of biting lice (Trichodectes canis)
A single dose of the veterinary medicinal product should be administered. A further
veterinary examination 30 days after treatment is recommended as some animals may
require a second treatment.
Treatment of ear mite infestation (Otodectes cynotis)
A single dose of the veterinary medicinal product should be administered. Loose debris
should be gently removed from the external ear canal at each treatment. A further
veterinary
examination 30 days after treatment is recommended as some animals may require a
second treatment. Do not apply directly to the ear canal.
AN: 01494/2024 & 02361/2024
Treatment of sarcoptic mange (caused by Sarcoptes scabiei
A single dose of the veterinary medicinal product should be administered twice 4 weeks
apart.
Prevention of heartworm disease (D. immitis) and cutaneous dirofilariosis (D. repens)
Dogs in areas endemic for heartworm, or those which have travelled to endemic areas,
may be infected with adult heartworms. Therefore prior to treatment with the veterinary
medicinal product, the advice provided in section 3.5 should be considered.
For prevention of heartworm disease and cutaneous dirofilariosis, the veterinary
medicinal product must be applied at regular monthly intervals during the time of the
year when mosquitoes (the intermediate hosts which carry and transmit
and D. repens
administered throughout the year or at least 1 month before the first expected
exposure to mosquitoes. Treatment should continue at regular monthly intervals until
1 month after the last exposure to mosquitoes. To establish a treatment routine, it is
recommended that the same day or date be used each month. When replacing
another heartworm preventative product in a heartworm prevention programme, the
first treatment with the veterinary medicinal product must be given within 1 month of
the last dose of the former medication.
In non-endemic areas there should be no risk of dogs having heartworm. Therefore,
they can be treated without special precautions.
Treatment of microfilariae (D. immitis)
The veterinary medicinal product should be administered monthly for two consecutive
months.
Treatment of cutaneous dirofilariosis (skin worm) (adult stages of Dirofilaria repens)
The veterinary medicinal product should be administered monthly for six consecutive
months.
Reduction of microfilariae (D. repens)
The veterinary medicinal product should be administered monthly for four consecutive
months. Efficacy against adult worms has not been shown. Adult worms may
continue to produce microfilariae.
Treatment and prevention of Angiostrongylus vasorum
A single dose of the veterinary medicinal product should be administered. A further
veterinary examination 30 days after treatment is recommended as some animals
may require a second treatment.
In endemic areas regular 4 weekly application will prevent angiostrongylosis and
patent infection with Angiostrongylus vasorum
AN: 01494/2024 & 02361/2024
Treatment of Crenosoma vulpis
A single dose of the veterinary medicinal product should be administered.
Prevention of Spirocerca lupi:
The veterinary medicinal product should be administered monthly.
Roundworm, hookworm and whipworm treatment (Toxocara canis, Ancylostoma
caninum, Uncinaria stenocephalaoxascaris leonina and Trichuris vulpis).
In areas endemic for heartworm, monthly treatment may significantly reduce the risk
of re-infection caused by the respective round-, hook- and whipworms. In areas non-
endemic for heartworm, the veterinary medicinal product can be used as part of a
seasonal prevention programme against fleas and gastrointestinal nematodes.
Studies have shown that monthly treatment of dogs will prevent infections caused by
Uncinaria stenocephala.
Method of administration
For external use only. Do not remove the pipette from the sachet until ready to use.
Remove the pipette from the outer sachet using scissors or fold along diagonal line to
expose nick; tear back at nick.
Hold the pipette upright. Tap the narrow part of the pipette to ensure the contents
remain within the main body of the pipette. Twist or snap back the tip.
For dogs up to 25 kg:
With the dog in a standing position, part the coat between the shoulder blades until
the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the
pipette on the skin and squeeze the pipette firmly several times to empty its contents
directly onto the skin.
AN: 01494/2024 & 02361/2024
For dogs of more than 25 kg:
For easy application the dog should be standing. The entire contents of the pipette
should be applied evenly as 3 or 4 spots along the top of the back, from between the
shoulders to the base of the tail. At each spot, part the coat until the skin is visible.
Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin
and gently squeeze the pipette to expel a portion of its contents directly onto the skin.
Do not apply an excessive amount of solution at any one spot, as that could cause
some of the veterinary medicinal product to run down the animal’s side.
Do not use in puppies under 7 weeks of age.
Do not use in cases of hypersensitivity to the active substances or to any of the
excipients.
Do not use in dogs classified as Class 4 for heartworm disease as the safety of the
veterinary medicinal product has not been evaluated in this animal group.
For cats, the corresponding veterinary medicinal product for cats, which contains 100
mg/ml imidacloprid and 10 mg/ml moxidectin, must be used.
For ferrets: Do not use the presentation for dogs. Only the corresponding veterinary
medicinal product for small cats and ferrets (0.4 ml) must be used.
Do not use on canaries.
Do not use in cases of hypersensitivity to the active substances or to any of the
excipients.
Do not use in dogs classified as Class 4 for heartworm disease as the safety of the
veterinary medicinal product has not been evaluated in this animal group.
For cats, the corresponding veterinary medicinal product for cats, which contains 100
mg/ml imidacloprid and 10 mg/ml moxidectin, must be used.
For ferrets: Do not use the presentation for dogs. Only the corresponding veterinary
medicinal product for small cats and ferrets (0.4 ml) must be used.
Do not use on canaries.
Target species: Dogs.
Common
(1 to 10 animals / 100 animals
treated):
Cough
, Tachypnoea
, Dyspnoea
Vomiting
, Diarrhoea
, Inappetence
,
Lethargy
Rare
(1 to 10 animals / 10,000 animals
treated):
Vomiting
Hypersensitivity
AN: 01494/2024 & 02361/2024
Page 5 of 12Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Application site greasy fur
, Application site
hair loss
, Application site itching
, Application
site reddening
,
Pruritus
,
Neurological signs (e.g. ataxia, muscle
tremor)
,
Hypersalivation
,
Behavioural disorders (e.g. agitation)
,
Lethargy
, Inappetence
1
These signs are common in heartworm positive dogs with microfilaraemia, and there
is a risk of gastrointestinal signs and severe respiratory signs that may require prompt
veterinary treatment.
Disappears without further treatment.
Transient.
If the animal licks the application site after treatment. Mostly transient.
If the animal licks the application site immediately after treatment. Not a sign of
intoxication; disappears within minutes.
Caused by a sensation at the application site. Correct application will minimise licking
of the application sites.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Common
(1 to 10 animals / 100 animals
treated):
Cough
, Tachypnoea
, Dyspnoea
Vomiting
, Diarrhoea
, Inappetence
,
Lethargy
Rare
(1 to 10 animals / 10,000 animals
treated):
Vomiting
Hypersensitivity
AN: 01494/2024 & 02361/2024
Page 5 of 12Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Application site greasy fur
, Application site
hair loss
, Application site itching
, Application
site reddening
,
Pruritus
,
Neurological signs (e.g. ataxia, muscle
tremor)
,
Hypersalivation
,
Behavioural disorders (e.g. agitation)
,
Lethargy
, Inappetence
1
These signs are common in heartworm positive dogs with microfilaraemia, and there
is a risk of gastrointestinal signs and severe respiratory signs that may require prompt
veterinary treatment.
Disappears without further treatment.
Transient.
If the animal licks the application site after treatment. Mostly transient.
If the animal licks the application site immediately after treatment. Not a sign of
intoxication; disappears within minutes.
Caused by a sensation at the application site. Correct application will minimise licking
of the application sites.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Brief contact of the animal with water on one or two occasions between monthly
treatments is unlikely to significantly reduce the efficacy of the veterinary medicinal
product. However, frequent shampooing or immersion of the animal in water after
treatment may reduce the efficacy of the veterinary medicinal product.
Parasite resistance to any particular class of anthelmintic may develop following
frequent, repeated use of an anthelmintic of that class. Therefore, the use of this
veterinary medicinal product should be based on the assessment of each individual
case and on local epidemiological information about the current susceptibility of the
target species in order to limit the possibility of a future selection for resistance.
AN: 01494/2024 & 02361/2024
The use of the veterinary medicinal product should be based on the confirmed
diagnosis of mixed infection (or risk of infection, where prevention applies) at the same
time (see also sections 3.2 and 3.9).
The veterinary medicinal product has not been shown to have an adulticidal effect
against
field conditions.
Special precautions for safe use in the target species:
The treatment of dogs weighing less than 1 kg should be based on a risk-benefit
assessment.
There is limited experience on the use of the veterinary medicinal product in sick and
debilitated animals, thus the veterinary medicinal product should only be used based
on a risk-benefit assessment for these animals.
Care should be taken that the contents of the pipette or the applied dose does not come
into contact with the eyes or mouth of the recipient and/or other animals. Do not allow
recently treated animals to groom each other. When the veterinary medicinal product
is applied in 3 to 4 separate spots (see section 4.9), specific care should be taken to
prevent the animal licking the application sites.
This veterinary medicinal product contains moxidectin (a macrocyclic lactone),
therefore special care should be taken with Collies, Old English Sheepdogs and related
breeds or crossbreeds, to correctly administer the veterinary medicinal product as
described under section 4.9; in particular, oral uptake by the recipient and/or other
animals in close contact should be prevented.
The safety of the veterinary medicinal product has only been evaluated in dogs
classified as either Class 1 or 2 for heartworm disease in laboratory studies and in a
few Class 3 dogs in a field study. Therefore, the use in dogs with obvious or severe
symptoms of the disease should be based on a careful benefit risk assessment by the
treating veterinarian.
Although experimental overdosage studies have shown that the veterinary medicinal
product may be safely administered to dogs infected with adult heartworms, it has no
therapeutic effect against adult
dogs 6 months of age or more, living in areas endemic for heartworm, should be tested
for existing adult heartworm infection before being treated with the veterinary medicinal
product. At the discretion of the veterinarian, infected dogs should be treated with an
adulticide to remove adult heartworms. The safety of the veterinary medicinal product
has not been evaluated when administered on the same day as an adulticide.
Imidacloprid is toxic for birds, especially canaries.
AN: 01494/2024 & 02361/2024
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Avoid contact with skin, eyes or mouth.
Do not eat, drink or smoke during application.
Wash hands thoroughly after use.
In case of accidental spillage onto skin, wash off immediately with soap and water.
If the veterinary medicinal product accidentally gets into eyes, they should be
thoroughly flushed with water.
If skin or eye symptoms persist, or the veterinary medicinal product is accidentally
swallowed, seek medical advice immediately and show the package leaflet or label to
the physician.
Do not ingest. In case of accidental ingestion, seek medical advice immediately and
show the package leaflet or the label to the physician.
People with a known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin
should administer the veterinary medicinal product with caution.
In very rare cases the veterinary medicinal product may cause skin sensitisation or
transient skin reactions (for example numbness, irritation or burning/tingling sensation).
In very rare cases the veterinary medicinal product may cause respiratory irritation in
sensitive individuals.
In order to prevent children from getting access to pipettes, keep the pipette in the
original packaging until ready for use and dispose of used pipettes immediately.
After application do not stroke or groom animals until the application site is dry.
Treated animals should not be handled until the application site is dry, and children
should not be allowed to play with treated animals until the application site is dry. It is
therefore recommended that animals are not treated during the day, but should be
treated during the early evening, and that recently treated animals are not allowed to
sleep with owners, especially children.
Special precautions for the protection of the environment:
The veterinary medicinal product should not enter water courses as it has harmful
effects on aquatic organisms: moxidectin is highly toxic to aquatic organisms.
Dogs should not be allowed to swim in surface waters for 4 days after treatment.
Other precautions:
The solvent in the veterinary medicinal product may stain or damage certain materials
including leather, fabrics, plastics and finished surfaces. Allow the application site to
dry before permitting contact with such materials.
treatments is unlikely to significantly reduce the efficacy of the veterinary medicinal
product. However, frequent shampooing or immersion of the animal in water after
treatment may reduce the efficacy of the veterinary medicinal product.
Parasite resistance to any particular class of anthelmintic may develop following
frequent, repeated use of an anthelmintic of that class. Therefore, the use of this
veterinary medicinal product should be based on the assessment of each individual
case and on local epidemiological information about the current susceptibility of the
target species in order to limit the possibility of a future selection for resistance.
AN: 01494/2024 & 02361/2024
The use of the veterinary medicinal product should be based on the confirmed
diagnosis of mixed infection (or risk of infection, where prevention applies) at the same
time (see also sections 3.2 and 3.9).
The veterinary medicinal product has not been shown to have an adulticidal effect
against
field conditions.
Special precautions for safe use in the target species:
The treatment of dogs weighing less than 1 kg should be based on a risk-benefit
assessment.
There is limited experience on the use of the veterinary medicinal product in sick and
debilitated animals, thus the veterinary medicinal product should only be used based
on a risk-benefit assessment for these animals.
Care should be taken that the contents of the pipette or the applied dose does not come
into contact with the eyes or mouth of the recipient and/or other animals. Do not allow
recently treated animals to groom each other. When the veterinary medicinal product
is applied in 3 to 4 separate spots (see section 4.9), specific care should be taken to
prevent the animal licking the application sites.
This veterinary medicinal product contains moxidectin (a macrocyclic lactone),
therefore special care should be taken with Collies, Old English Sheepdogs and related
breeds or crossbreeds, to correctly administer the veterinary medicinal product as
described under section 4.9; in particular, oral uptake by the recipient and/or other
animals in close contact should be prevented.
The safety of the veterinary medicinal product has only been evaluated in dogs
classified as either Class 1 or 2 for heartworm disease in laboratory studies and in a
few Class 3 dogs in a field study. Therefore, the use in dogs with obvious or severe
symptoms of the disease should be based on a careful benefit risk assessment by the
treating veterinarian.
Although experimental overdosage studies have shown that the veterinary medicinal
product may be safely administered to dogs infected with adult heartworms, it has no
therapeutic effect against adult
dogs 6 months of age or more, living in areas endemic for heartworm, should be tested
for existing adult heartworm infection before being treated with the veterinary medicinal
product. At the discretion of the veterinarian, infected dogs should be treated with an
adulticide to remove adult heartworms. The safety of the veterinary medicinal product
has not been evaluated when administered on the same day as an adulticide.
Imidacloprid is toxic for birds, especially canaries.
AN: 01494/2024 & 02361/2024
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Avoid contact with skin, eyes or mouth.
Do not eat, drink or smoke during application.
Wash hands thoroughly after use.
In case of accidental spillage onto skin, wash off immediately with soap and water.
If the veterinary medicinal product accidentally gets into eyes, they should be
thoroughly flushed with water.
If skin or eye symptoms persist, or the veterinary medicinal product is accidentally
swallowed, seek medical advice immediately and show the package leaflet or label to
the physician.
Do not ingest. In case of accidental ingestion, seek medical advice immediately and
show the package leaflet or the label to the physician.
People with a known hypersensitivity to benzyl alcohol, imidacloprid or moxidectin
should administer the veterinary medicinal product with caution.
In very rare cases the veterinary medicinal product may cause skin sensitisation or
transient skin reactions (for example numbness, irritation or burning/tingling sensation).
In very rare cases the veterinary medicinal product may cause respiratory irritation in
sensitive individuals.
In order to prevent children from getting access to pipettes, keep the pipette in the
original packaging until ready for use and dispose of used pipettes immediately.
After application do not stroke or groom animals until the application site is dry.
Treated animals should not be handled until the application site is dry, and children
should not be allowed to play with treated animals until the application site is dry. It is
therefore recommended that animals are not treated during the day, but should be
treated during the early evening, and that recently treated animals are not allowed to
sleep with owners, especially children.
Special precautions for the protection of the environment:
The veterinary medicinal product should not enter water courses as it has harmful
effects on aquatic organisms: moxidectin is highly toxic to aquatic organisms.
Dogs should not be allowed to swim in surface waters for 4 days after treatment.
Other precautions:
The solvent in the veterinary medicinal product may stain or damage certain materials
including leather, fabrics, plastics and finished surfaces. Allow the application site to
dry before permitting contact with such materials.
During treatment with the veterinary medicinal product no other antiparasitic
macrocyclic lactone should be administered. No interactions between the veterinary
medicinal product and routinely used veterinary medicinal products or medical or
surgical procedures have been observed.
Safety of the veterinary medicinal product when administered on the same day as an
adulticide to remove adult heartworms has not been evaluated.
macrocyclic lactone should be administered. No interactions between the veterinary
medicinal product and routinely used veterinary medicinal products or medical or
surgical procedures have been observed.
Safety of the veterinary medicinal product when administered on the same day as an
adulticide to remove adult heartworms has not been evaluated.
Do not store above 25 °C.
Store in the original package in order to protect from light and moisture.
Store in the original package in order to protect from light and moisture.
Not applicable.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Imidacloprid
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Advantage 100 mg Spot-on Solution for Medium Dogs
AVM-GSLElanco GmbH
spot-on
Dogs
Advantage 100 mg Spot-on Solution for Medium Dogs
AVM-GSLElanco GmbH
spot-on
Dogs
Advantage 100 Spot-on Solution for Dogs
NFA-VPSElanco GmbH
spot-on
Dogs
Advantage 100 Spot-on Solution for Dogs
NFA-VPSElanco GmbH
spot-on
Dogs
Advantage 250 mg Spot-on Solution for Large Dogs
AVM-GSLElanco GmbH
spot-on
Dogs
Advantage 250 mg Spot-on Solution for Large Dogs
AVM-GSLElanco GmbH
spot-on
Dogs
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
Flea & Tick Treatments for Dogs
Vet-strength flea and tick treatments at pharmacy prices. Frontline, Advocate, Bravecto, Nexgard and more.
From £8.99
Shop now
Pharmacy2U
Pet Flea Treatments at Pharmacy2U
Frontline, Advantage and own-brand flea treatments at pharmacy prices. Trusted UK pharmacy since 1999.
From £7.99
Shop now
VetBox
VetBox Flea & Worm Protection for Dogs
Vet-founded monthly parasite subscription. Flea, tick and worm protection delivered to your door. Founded by Dr Will Woodley, protecting 30,000+ pets.
From £9.99/month
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in flea-tick
Related Medications
Advantage 100 mg Spot-on Solution for Medium Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Advantage 100 mg Spot-on Solution for Medium Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Advantage 100 Spot-on Solution for Dogs
NFA-VPSImidacloprid
spot-on
Dogs
Advantage 100 Spot-on Solution for Dogs
NFA-VPSImidacloprid
spot-on
Dogs
Advantage 250 mg Spot-on Solution for Large Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Advantage 250 mg Spot-on Solution for Large Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.